D
Douglas B. Kell
Researcher at University of Liverpool
Publications - 657
Citations - 55792
Douglas B. Kell is an academic researcher from University of Liverpool. The author has contributed to research in topics: Systems biology & Dielectric. The author has an hindex of 111, co-authored 634 publications receiving 50335 citations. Previous affiliations of Douglas B. Kell include Max Planck Society & University of Wales.
Papers
More filters
Journal ArticleDOI
The dormant blood microbiome in chronic, inflammatory diseases
TL;DR: Overall, it seems that many more chronic, non-communicable, inflammatory diseases may have a microbial component than are presently considered, and may be treatable using bactericidal antibiotics or vaccines.
Journal ArticleDOI
Dormancy in non-sporulating bacteria
TL;DR: "All stood amazed, until an old woman, tottering out from among the crowd, put her hand to her brow, and peering under it in his face for a moment exclaimed, 'Sure enough! it is Rip Van Winkle-it is himself!'
Journal ArticleDOI
On the functional proton current pathway of electron transport phosphorylation: An electrodic view
TL;DR: The chemiosmotic and local proton hypotheses are tested and results from the measurement of chromatophores and submitochondrial particles suggest that the proton-proton coupling in electron transport phosphorylation is driven by proton starvation.
Journal ArticleDOI
Text mining and its potential applications in systems biology
TL;DR: By adding meaning to text, text mining techniques produce a more structured analysis of textual knowledge than simple word searches, and can provide powerful tools for the production and analysis of systems biology models.
Journal ArticleDOI
Systems biology, metabolic modelling and metabolomics in drug discovery and development.
TL;DR: There is increasing convergence between the number of human metabolites estimated via genomics and the number measured experimentally, and it is thus both timely, and now possible, to bring these two approaches together as an integrated whole to help understand the genesis of metabolic biomarkers, the progress of disease, and the modes of action, efficacy, off-target effects and toxicity of pharmaceutical drugs.